Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

Abstract Introduction Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways. This study evaluated spebrutinib pharmacology and mechanism of action over a 4-week treatment period in p...

Full description

Bibliographic Details
Main Authors: Peter H. Schafer, Alan J. Kivitz, Jianglin Ma, Shimon Korish, Donna Sutherland, Li Li, Ada Azaryan, Jolanta Kosek, Mary Adams, Lori Capone, Eun Mi Hur, Douglas R. Hough, Garth E. Ringheim
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-11-01
Series:Rheumatology and Therapy
Subjects:
Background methotrexate therapy
Bruton’s tyrosine kinase inhibitor
CC-292
Rheumatoid arthritis
Spebrutinib
Online Access:http://link.springer.com/article/10.1007/s40744-019-00182-7

Internet

http://link.springer.com/article/10.1007/s40744-019-00182-7

Similar Items